» Articles » PMID: 30925716

The Rise of Valley Fever: Prevalence and Cost Burden of Coccidioidomycosis Infection in California

Overview
Publisher MDPI
Date 2019 Mar 31
PMID 30925716
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Coccidioidomycosis (CM) is a fungal infection endemic in the southwestern United States (US). In California, CM incidence increased more than 213% (from 6.0/100,000 (2014) to 18.8/100,000 (2017)) and continues to increase as rates in the first half of 2018 are double that of 2017 during the same period. This cost-of-illness study provides essential information to be used in health planning and funding as CM infections continue to surge. We used a "bottom-up" approach to determine lifetime costs of 2017 reported incident CM cases in California. We defined CM natural history and used a societal approach to determine direct and discounted indirect costs using literature, national datasets, and expert interviews. The total lifetime cost burden of CM cases reported in 2017 in California is just under $700 million US dollars, with $429 million in direct costs and $271 million in indirect costs. Per person direct costs were highest for disseminated disease ($1,023,730), while per person direct costs were lowest for uncomplicated CM pneumonia ($22,039). Cost burden varied by county. This is the first study to estimate total costs of CM, demonstrating its huge cost burden for California.

Citing Articles

The Burden of Hospital Illness Associated with Disseminated Versus Isolated Pulmonary Coccidioidomycosis in the United States.

Coleman C, Bylyku J, Latifi A, Lovelace B, Shan R, Miriyapalli L J Fungi (Basel). 2025; 11(2).

PMID: 39997455 PMC: 11855934. DOI: 10.3390/jof11020161.


Estimating the Exposure-Response Relationship between Fine Mineral Dust Concentration and Coccidioidomycosis Incidence Using Speciated Particulate Matter Data: A Longitudinal Surveillance Study.

Weaver A, Keeney N, Head J, Heaney A, Camponuri S, Collender P Environ Health Perspect. 2025; 133(1):17003.

PMID: 39804964 PMC: 11729455. DOI: 10.1289/EHP13875.


The Known and Unknown "Knowns" of Human Susceptibility to Coccidioidomycosis.

Hsu A J Fungi (Basel). 2024; 10(4).

PMID: 38667927 PMC: 11051025. DOI: 10.3390/jof10040256.


Orbital Osteomyelitis and Periorbital Abscess Due to Coccidioidomycosis Following Trauma.

Hayashi G, Pardo N, Hirsh N, Vijayan V Cureus. 2023; 15(10):e46586.

PMID: 37933359 PMC: 10625754. DOI: 10.7759/cureus.46586.


Differentiating Lung Nodules Due to from Those Due to Lung Cancer Based on Radiographic Appearance.

Peterson M, Jain R, Hildebrandt K, Carson W, Fayed M J Fungi (Basel). 2023; 9(6).

PMID: 37367577 PMC: 10302563. DOI: 10.3390/jof9060641.


References
1.
Gould M, Sanders G, Barnett P, Rydzak C, Maclean C, McClellan M . Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med. 2003; 138(9):724-35. DOI: 10.7326/0003-4819-138-9-200305060-00009. View

2.
Williams A . Calculating the global burden of disease: time for a strategic reappraisal?. Health Econ. 1999; 8(1):1-8. DOI: 10.1002/(sici)1099-1050(199902)8:1<1::aid-hec399>3.0.co;2-b. View

3.
Chang D, Anderson S, Wannemuehler K, Engelthaler D, Erhart L, Sunenshine R . Testing for coccidioidomycosis among patients with community-acquired pneumonia. Emerg Infect Dis. 2008; 14(7):1053-9. PMC: 2600364. DOI: 10.3201/eid1407.070832. View

4.
Barnato A, Sanders G, Owens D . Cost-effectiveness of a potential vaccine for Coccidioides immitis. Emerg Infect Dis. 2001; 7(5):797-806. PMC: 2631863. DOI: 10.3201/eid0705.010505. View

5.
Ampel N . The diagnosis of coccidioidomycosis. F1000 Med Rep. 2010; 2. PMC: 2948390. DOI: 10.3410/M2-2. View